Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...

Recent health news covers a proposed increase in Medicare Advantage rates, access challenges to precision cancer drugs for ...

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...

South African private hospital operator Life Healthcare on Monday announced the sale of its radiopharmaceuticals business LMI to U.S.-listed Lantheus Holdings , sending its Johannesburg-listed shares ...

Leo Pharma, meanwhile, announced this fall that it had submitted its delgocitinib cream for FDA approval as a treatment for adults with moderate to severe CHE for whom topical corticosteroids ...

Defence Space Agency Director General Air Vice Marshal Pawan Kumar says the defence forces were also looking at collaborating ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.